Endo, Inc.

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It is also involved in the developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The company offers ADRENALIN, a non-selective alpha- and beta-adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; and VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It also provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.